Received Nov 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | — |
RSV; This spontaneous case was reported by a consumer and describes the occurrence of RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) in a female patient of an unknown age who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. Currently, the patient had enough problems and did not want to add it. On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (unknown route) 1 dosage form. On an unknown date, the patient experienced RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV). At the time of the report, RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) outcome was unknown. The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Unknown) was unknown. Concomitant medication use information was not provided by reporter. The patient received all Moderna COVID vaccinations. The reporter called the global contact center to ask about locating the mRESVIA vaccine. The patient had RSV disease. The patient had it before and was told they had to wait 2 weeks afterward to get it. The patient had RSV and has not had an RSV vaccine because the patient forgot all about it after 2 weeks. It was unknown if the patient experienced any additional symptoms/events. Treatment medication use information was not provided by reporter. This case was linked to US-MODERNATX, INC.-MOD-2025-791540 (E2B Linked Report).; Sender's Comments: US-MODERNATX, INC.-MOD-2025-791540:Same reporter, different patient (Multiple Patient's case)